Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Medicinal Chemistry|September 25, 2025
Proteome-Wide Ligand and Target Discovery by Using Covalent Probes and Natural ProductsJingqing Liu, Chaoming Huang, Shengrong Li, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|March 11, 2022
Targeted inhibition of ZAK ameliorates renal interstitial fibrosisShuangshuang Shu, Han Liu, Jianzhang Yang, et al.
Journal of Medicinal Chemistry|June 28, 2019
Design, Synthesis, and Structure-Activity Relationships of 1,2,3-Triazole Benzenesulfonamides as New Selective Leucine-Zipper and Sterile-α Motif Kinase (ZAK) InhibitorsJianzhang Yang, Marthandam Asokan Shibu, Lulu Kong, et al.
Bioorganic & Medicinal Chemistry Letters|May 24, 2016
Optimization of isoxazoline amide benzoxaboroles for identification of a development candidate as an oral long acting animal ectoparasiticideYong-Kang Zhang, Jacob J Plattner, Eric E Easom, et al.
Journal of Medicinal Chemistry|August 8, 2022
Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13Jianzhang Yang, Yu Chang, Jean Ching-Yi Tien, et al.
Journal of Medicinal Chemistry|October 10, 2024
Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC DegraderLicheng Zhou, Kaijie Zhou, Yu Chang, et al.
Journal of Medicinal Chemistry|March 13, 2025
Discovery of YJZ5118: A Potent and Highly Selective Irreversible CDK12/13 Inhibitor with Synergistic Effects in Combination with Akt InhibitionJianzhang Yang, Yu Chang, Kaijie Zhou, et al.
Biorxiv : the Preprint Server for Biology|May 7, 2026
Rewiring Oncogenic Transcriptional Complexes with Domain-ALTeration Chimeras (DALTACs) in Prostate CancerJie Luo, Jianzhang Yang, Jean Ching-Yi Tien, et al.
Cell Reports. Medicine|October 1, 2024
Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibitionYu Chang, Xiaoju Wang, Jianzhang Yang, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 12, 2025
Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinomaJean Ching-Yi Tien, Yali Zhai, Rong Wu, et al.
Pageof 2